Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• "Moderate Buy" is the average recommendation from five analysts (1 sell, 3 buy, 1 strong buy) with an average 12‑month price target of $10.00, versus the stock's recent price near $1.47.
• Metagenomi missed quarterly estimates—EPS ($0.60) and revenue $3.91M—shows a steep negative net margin (~348%) and analysts forecast about -2.46 EPS for the current fiscal year, signaling weak fundamentals.
• Several institutional investors, including Renaissance Technologies, Jane Street and Pura Vida Investments, have recently increased their stakes, reflecting growing institutional interest despite the company's losses.

Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $10.00.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Metagenomi in a research note on Monday, December 22nd.

Metagenomi Stock Performance

MGX opened at $1.47 on Friday. Metagenomi has a one year low of $1.23 and a one year high of $3.95. The company has a market capitalization of $55.30 million, a PE ratio of -0.62 and a beta of 0.45. The stock's fifty day moving average is $1.57 and its 200-day moving average is $1.91.

Metagenomi (NASDAQ:MGX - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.02). The business had revenue of $3.91 million for the quarter, compared to the consensus estimate of $7.33 million. Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%. On average, equities research analysts forecast that Metagenomi will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Metagenomi

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC boosted its stake in shares of Metagenomi by 260.1% during the 2nd quarter. Pura Vida Investments LLC now owns 952,134 shares of the company's stock valued at $1,409,000 after buying an additional 687,743 shares during the period. Renaissance Technologies LLC increased its holdings in Metagenomi by 276.3% in the fourth quarter. Renaissance Technologies LLC now owns 628,400 shares of the company's stock worth $1,018,000 after buying an additional 461,400 shares during the last quarter. Peapod Lane Capital LLC boosted its holdings in Metagenomi by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 513,815 shares of the company's stock valued at $1,218,000 after acquiring an additional 5,706 shares during the period. Jane Street Group LLC raised its stake in Metagenomi by 341.6% during the 4th quarter. Jane Street Group LLC now owns 433,859 shares of the company's stock valued at $703,000 after purchasing an additional 335,604 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in shares of Metagenomi by 102.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company's stock valued at $641,000 after purchasing an additional 200,000 shares during the period.

About Metagenomi

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.